<DOC>
	<DOCNO>NCT00079456</DOCNO>
	<brief_summary>This phase II trial study well temsirolimus work treat patient relapsed refractory multiple myeloma . Drugs use chemotherapy temsirolimus work different way stop cancer cell divide stop grow die .</brief_summary>
	<brief_title>Temsirolimus Treating Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine overall response rate patient relapse refractory multiple myeloma treat CCI-779 . SECONDARY OBJECTIVES : I . Determine progression-free survival patient treated drug . II . Determine toxicity drug patient . III . Determine presence PTEN mutation patient treat drug . IV . Correlate pharmacokinetics drug response patient . V. Correlate pharmacodynamic effect drug response patient . OUTLINE : This open-label study . Patients receive temsirolimus IV 30 minute day 1 , 8 , 15 , 21 . Courses repeat every 28 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Diagnosis multiple myeloma ( MM ) SalmonDurie stage IIA IIIA OR progressive stage IA disease Meets least 1 major AND 1 minor criterion OR least 3 minor criterion The following consider major criterion : Plasmacytoma tissue biopsy Bone marrow plasmacytosis &gt; = 30 % plasma cell Monoclonal globulin spike serum protein electrophoresis exceed 3.5 g/dL immunoglobulin ( Ig ) G peak 2.0 g/dL IgA peak OR presence BenceJones protein &gt; = 1 g/24 hoururine collection The following consider minor criterion : Bone marrow plasmacytosis 1029 % Monoclonal globulin spike present , less level define major criterion Lytic bone lesion Decrease normal IgM &lt; 50 mg/dL , IgA &lt; 100 mg/dL , IgG &lt; 600 mg/dL No nonsecretory MM ( absent serum urinary Mprotein ) Failed least 1 prior systemic therapy* ( e.g. , chemotherapy , highdose corticosteroid , thalidomide , bortezomib ) treatment MM No solitary plasmacytoma Performance status ECOG 02 More 6 month Absolute neutrophil count &gt; 1,200/mm^3 Platelet count &gt; 75,000/mm^3 AST ALT = &lt; 2.5 time upper limit normal ( ULN ) Bilirubin = &lt; 1.5 time ULN Creatinine = &lt; 1.5 time ULN No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Fasting cholesterol = &lt; 350 mg/dL Triglycerides = &lt; 400 mg/dL No concurrent uncontrolled illness No active ongoing infection require oral IV antibiotic No prior allergic reaction compound similar chemical biological composition CCI779 No prior concurrent malignancy myelodysplasia except follow : Basal cell squamous cell skin cancer Carcinoma situ cervix Localized cancer treat surgery evidence disease &gt; 5 year No psychiatric illness social situation would preclude study compliance More 4 week since prior thalidomide recover Prior highdose chemotherapy stem cell transplantation allow More 4 week since prior chemotherapy recover More 4 week since prior highdose corticosteroid recover More 4 week since prior bortezomib recover More 4 week since prior antimyeloma systemic therapy recover No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>